Abstract
There is highlighted special small subgroup of patients with non-small cell lung cancer who has translocation of gene ALK in tumor. The modified gene encodes a fusion of pathological protein, leading to activation of ALK receptor on the membrane of tumor cells and then malignant transformation. Clinical studies of crizotinib noted a high frequency (> 60%) of complete and partial responses in chemoresistant metastatic ALK-positive lung cancer; median of progression-free survival reached more than 9 months. Crizotinib is the ATP competitive inhibitor of tyrosine kinase receptor like ALK, MET and ROS1, is one of the most effective drugs for the treatment ofALK-positive lung cancer. However, it is almost inevitable that almost all patients, even in the most pronounced immediate effect to 24 months of treatment crizotinib marked progression of the disease, which is associated with the development of tumor resistance. Currently, clinical studies of the second generation inhibitors of tyrosine kinases, such as ceritinib, alectinib, AP26113 etc, are continuing. Their application is possible in case of the development of resistance to crizotinib.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
